PRODUCT INFORMATION



6-hydroxy Melatonin

Item No. 21857

CAS Registry No.: 2208-41-5


Formal Name: N-[2-(6-hydroxy-5-methoxy-1H-indol-3-yl)ethyl]-acetamide

Synonym: 6-OHM MF: $C_{13}H_{16}N_2O_3$ FW: 248.3 **Purity:**

 λ_{max} : 219, 303 nm A crystalline solid UV/Vis.: Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

6-hydroxy Melatonin is supplied as a crystalline solid. A stock solution may be made by dissolving the 6-hydroxy melatonin in the solvent of choice, which should be purged with an inert gas. 6-hydroxy Melatonin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of 6-hydroxy melatonin in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF. 6-hydroxy Melatonin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, 6-hydroxy melatonin should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. 6-hydroxy Melatonin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

6-hydroxy Melatonin is an active metabolite of melatonin (Item No. 14427).¹⁻⁵ It is formed from melatonin by the cytochrome P450 (CYP) isoform CYP1A2 in human liver microsomes⁶ 6-hydroxy Melatonin is a melatonin 1A (MT $_{1A}$), MT $_{1B}$, and MT $_{2}$ receptor agonist. 1,2 It inhibits dopamine release from isolated rabbit retina (IC₅₀ = $0.0016 \mu \dot{M}$). 6-hydroxy Melatonin (10 and 100 $\mu \dot{M}$) reduces increases in the levels of NF-κB, IL-6, and IL-8 and decreases in glutathione (GSH) levels in LPS- and peptidoglycan G-stimulated human umbilical vein endothelial cells (HUVECs) in an in vitro model of sepsis.⁴ It reduces iron-induced lipid oxidation in rat hippocampal homogenate when administered at a dose of 10 mg/kg.⁵

References

- 1. Dubocovich, M.L., Masana, M.I., Iacob, S., et al. Naunyn-Schmiedeberg's Arch. Pharmacol. 355(3), 365-375 (1997).
- 2. Dubocovich, M.L. Trends Pharamacol. Sci. 16(2), 50-56 (1995).
- 3. Dubocovich, M.L. J. Pharmacol. Exp. Ther. 234(2), 395-401 (1985).
- 4. Lowes, D.A., Almawash, A.M., Webster, N.R., et al. Br. J. Anaesth. 107(2), 193-201 (2011).
- 5. Maharaj, D.S., Maharaj, H., Daya, S., et al. J. Neurochem. 96(1), 78-81 (2006).
- 6. Härtter, S., Wang, X., Weigmann, H., et al. J. Clin. Psychopharmacol. 21(2), 167-174 (2001).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM